Octapharma plays prominent role at hemophilia conference

Independent Swiss biotech firm Octapharma is playing a prominent role this week at the International Society on Thrombosis and Hemostasis (ISTH) Congress in Berlin, Germany.

As a platinum sponsor of the congress, Octapharma's active involvement included two sponsored scientific symposia, one of which was dedicated to exploring recent data and real-world experiences with Nuwiq (simoctocog alfa), an antihemophilic factor (recombinant).

The safety and efficacy of Nuwiq, which was approved in Europe in 2014 and in the USA in 2015 as an intravenous therapy for adults and children living with hemophilia A, has already been demonstrated in seven clinical trials. This most recent data, presented during the ISTH symposium, focused on using Nuwiq to treat previously untreated patients (PUPs) as well as on a pharmacokinetic (PK)-based personalized approach to optimizing dosage during hemophilia treatment (NuPreviq).